Follow the enGene Therapeutics Inc. share price and the full management transaction log of the company, a listed equity based in Canada. Shares are listed on the CA market, under the supervision of SEDI. Market capitalisation: €119.2m. The latest transaction was filed on 24 July 2026 (00 - Opening Balance-Initial SEDI Report). Among the most active insiders: Richton, Kathleen Patricia. Every trade is openly available.
18
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate enGene Therapeutics Inc. Hold (neutral), based on 7 analysts. Average price target: US$3.29.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
enGene Therapeutics Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias génicas para enfermedades graves. Cotiza en la Bolsa de Valores de Toronto bajo el símbolo XTSE.